A new drug has been developed at Houston Methodist Hospital that targets GBM, the most aggressive form of brain cancer, and other incurable brain cancers while sparing normal brain cells.
This smart drug targets only the deadliest brain cancer cells while being non-toxic to normal brain tissue. Glioblastoma multiforme (GBM) is an incurable form of brain cancer. Temozolamide is a drug which is used to prolong the lives of patients with this aggressive form of cancer. However, chemotherapy resistance has meant that the effectiveness of this drug is limited.
It has been discovered in an animal form of human brain cancer that the action of combining chemotherapy with the new smart drug prolonged life more than six-fold. The clinical study carried out at Houston Methodist Hospital showed that the research team had managed to invent a way in which to conquer chemotherapy drug resistance and target the aggressive brain cancer cells while sparing the surrounding normal healthy brain tissue.
Clinical trials are run by different institutions and drug companies, and professional experienced staff are essential to a successful and clearly monitored study. Pharmaceutical consulting allows the best in the business to advise on clinical research projects, ensuring the very best practice is carried out and a full and comprehensive analysis is determined on completion of the study. Publishing results is important for doctors, scientists and patients, so carrying out a professional clinical trial on any new drugs is paramount. Companies such as http://www.gandlscientific.com/pharmaceutical-consulting provide expert service and personnel for research trials.
The trial results from this study demonstrated how this smart drug does no damage to normal brain cells, but in GBM cells it is transformed into a compound chemical that blocks chemotherapy resistance, and this in turn allows for the destruction of deadly brain tumours.
Brain cancers, including GBM, express high levels of MOAB, otherwise known as Monoamine Oxidase B. This protein causes a reaction that changes the inactive drug into a new compound that stops chemotherapy resistance from occurring.
The results so far support more testing of the PAM-OBG drug. Further studies will determine whether this potential drug candidate is an effective form of treatment for patients suffering with GBM or other aggressive brain cancers that exhibit high levels of the MOAB protein.